Completed PHASE2 INTERVENTIONAL 3-arm NCT00185380

Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)

Multi-center, Open, Randomized, Dose Finding Phase II Study to Investigate Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) Releasing Different Amounts of Levonorgestrel Compared to MIRENA in Nulliparous and Parous Women in Need of Contraception.

Sponsor: Bayer

Conditions Contraception

Interventions Levonorgestrel IUS (BAY86-5028, G04209B) Levonorgestrel IUS (BAY86-5028, G04209C) Levonorgestrel IUS (Mirena, BAY86-5028)

Updated 6 times since 2017 Last updated: May 15, 2015 Started: Apr 30, 2005 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Contraception, this trial is completed. The trial is conducted by Bayer and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Békéscsaba, Hungary , Chesterfield, United Kingdom , Drammen, Norway , Eger, Hungary , Elverum, Norway , Espoo, Finland , Gothenburg, Sweden , Helsinki, Finland , Huddinge, Sweden , Joensuu, Finland and 20 more locations